Company intelligence / Profile preview

MultiGene Vascular Systems

Ownership: Private
Development stage: Preclinical

Overview

MultiGene Vascular Systems developed MultiGeneAngio, an autologous cell-based gene therapy targeting severe peripheral arterial disease. Two Phase I/II studies were conducted to assess safety and preliminary efficacy in patients with chronic critical limb ischemia and intermittent claudication. No published late-stage results or approvals are available; the most recent trial was active but not recruiting as of early 2025. Literature supports the approach of co-expressing angiogenic/regenerative genes to improve vascular graft patency[1].

Therapeutic areas: Cardiovascular
Modalities: Cell therapyGene therapy
Industry: Biotech

Drug pipeline

1 asset

AIP cells

Pre-clinical

Indications: Type 1 Diabetes, Type 2 Diabetes

Beyond the preview

Go deeper on MultiGene Vascular Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MultiGene Vascular Systems.

Explore the full profile